Skip to main content

Table 2 Univariable and multivariable analysis of total and subgroups of gastric cancer patients

From: Regulatory T cells and M2 macrophages present diverse prognostic value in gastric cancer patients with different clinicopathologic characteristics and chemotherapy strategies

 

Univariable

Multivaraible

p-value

HR

95% CI

p-value

HR

95% CI

Total

 CD163 High vs Low

0.014

1.334

1.059

1.273

0.024*

1.335

1.04

1.715

 PD-L1 Pos vs Neg

< 0.001

0.521

0.396

0.687

0.087

0.775

0.579

1.038

 CD3 High vs Low

0.031

0.776

0.616

0.978

0.456

0.906

0.698

1.175

 CD8 High vs Low

0.008

0.731

0.58

0.921

0.037*

0.75

0.573

0.982

 FOXP3lowCD163low

0.012

0.719

0.557

0.929

    

Stage I–II

 FOXP3 High vs Low

< 0.001

0.231

0.112

0.474

< 0.001*

0.207

0.100

0.426

Stage III–IV

 CD8 High vs Low

0.005

0.694

0.537

0.897

0.003*

0.661

0.502

0.871

 FOXP3lowCD163low

< 0.001

0.547

0.408

0.734

< 0.001*

0.561

0.407

0.774

N+

 PD-L1 Pos vs Neg

0.001

0.535

0.373

0.768

0.011*

0.621

0.431

0.895

 CD3 High vs Low

0.017

0.728

0.561

0.946

0.333

0.864

0.643

1.161

 CD8 High vs Low

0.004

0.679

0.523

0.883

0.035*

0.719

0.53

0.977

 FOXP3lowCD163low

0.003

0.651

0.488

0.868

0.007*

0.654

0.479

0.892

Upper

 FOXP3highPD-L1neg

< 0.001

2.623

1.666

4.13

0.002*

2.123

1.309

3.443

Middle

 PD-L1 Pos vs Neg

0.005

0.443

2.252

 

0.075

0.594

0.336

1.053

 CD8 High vs Low

0.029

0.606

0.387

 

0.015*

0.567

0.358

0.896

Lower

 PD-L1 Pos vs Neg

0.003

0.55

0.37

0.819

0.522

0.869

0.566

1.334

 CD8 High vs Low

0.034

0.692

0.492

0.973

0.042*

0.692

0.485

0.987

Tub

 CD163 High vs Low

0.040

1.647

1.022

2.653

0.026*

1.765

1.071

2.908

 PD-L1 Pos vs Neg

0.002

0.462

0.281

0.759

    

 FOXP3highPD-L1neg

0.014

1.868

1.137

3.070

0.227

1.387

0.815

2.316

Por

 FOXP3 High vs Low

0.018

1.442

1.065

1.951

0.949

0.988

0.691

1.414

 CD163 High vs Low

0.015

1.462

1.075

1.989

0.277

1.215

0.855

1.724

 CD3 High vs Low

0.002

0.617

0.458

0.832

0.246

0.814

0.574

1.153

 CD8 High vs Low

0.01

0.677

0.502

0.913

0.499

0.883

0.617

1.266

Sig+Muc

 FOXP3highCD163high

0.029

0.206

0.05

0.852

0.011*

0.154

0.036

0.656

“a+b+c”

 FOXP3lowCD163low

0.001

0.319

0.161

0.634

0.001*

0.319

0.161

0.634

“a+b”

 FOXP3 High vs Low

0.006

0.502

0.308

0.818

0.022*

0.563

0.344

0.92

 CD8 High vs Low

0.003

0.506

0.323

0.793

0.006*

0.533

0.34

0.837

  1. HR hazard ratio, CI confidence interval; N+: with lymph node metastasis; Pap: papillary adenocarcinoma; Tub: tubular adenocarcinoma; Por: poor-differentiated adenocarcinoma; Sig: signet ring cell addenocaecinoma; Muc: mucinous adenocarcinoma; “a+b+c”: chemotherapy with fluorouracil cisplatin and paclitaxel; “a+b”: chemotherapy with fluorouracil and cisplatin
  2. * p-value < 0.05 in multivariable analysis